Overcoming Challenges In Cell And Gene Therapy Containment

By Vidya Murthy, Director, Strategic Marketing, Advanced Therapies, and Kok Li, Kwang, Senior Manager, TCS, AP

The cell and gene therapy (CGT) market is growing rapidly, and this growth is partly attributable to the fact that CGTs are increasingly important healthcare solutions. CGTs typically target genetic diseases or diseases with very high unmet needs and limited existing therapeutic options, so quickly getting these life-altering therapies to the market is critical for patients.

New companies are emerging to develop cell, gene, and RNA therapeutics. There are currently more than 1,000 companies working on CGTs globally.² In addition, strong investor interest is leading to an influx of capital funding, and regulatory pathways are opening to provide more opportunities for expedited approval.

Each of the drugs in development or trials has a high value, reaching hundreds of dollars per dose. For this reason, robust packaging is of utmost importance. CGTs often involve the use of delicate biological materials, such as live cells or genetic material, which must be carefully protected during transport and storage. Inadequate packaging can result in the degradation or contamination of these materials.

This paper will review some hurdles that can slow your time to market, including the challenges in packaging these high-value therapies, and proven West solutions to help you mitigate risk and simplify the journey.